Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan to slow aortic root dilatation in Marfan-type heritable thoracic aortic disease
2022-000513-14Phase 3Active
- Sponsor
- Medical University of Gdańsk
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Marfan syndrome (MFS) and Familial aortopathies (h-TAAD) comparing Valsartan with Placebo (2 arms). Primary endpoint: Annual change in aortic root diameter (mm/year). Started Oct 2022; status: active.
02
Drugs
valsartan
03
Conditions
Marfan syndrome (MFS)Familial aortopathies (h-TAAD)
Beyond the preview
Go deeper on 2022-000513-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000513-14.